INTRODUCTION
Endometrioid adenocarcinoma (EAC) is the most prevalent gynecologic cancer in the United States and accounts for nearly 50 000 incident cases annually. 1 Contemporary molecular characterization of EAC has unearthed additional deleterious mutations and mechanisms responsible for tumor development. 2 One of the most common mutations detected in the more prevalent Type 1 EAC is the loss of the tumor suppressor gene, Pten (phosphatase and tensin homolog) and its phosphatase protein product. 3, 4 Pten mutations resulting in PTEN loss are involved in a wide variety of human cancers, including 460% of EACs of the endometrium. 3, 4 The deleterious phenotype resulting from Pten loss has also been observed in in vitro and in vivo tumor models. [5] [6] [7] [8] [9] Although constitutive deletion of Pten results in embryonic loss, conditional deletion of Pten in target cells has permitted exploration of spontaneous tumorigenesis in various tissues. [10] [11] [12] For EAC, a conditional Pten deletion within the endometrial epithelium leads to development of endometrial hyperplasia and Type I EAC in female mice. 5 Furthermore, the knockout of Pten by the progesterone receptor (PR)-driven Cre-recombinase progresses along the histologic continuum of complex atypical endometrial hyperplasia to EAC, thereby facilitating specific interrogation of Pten-driven EAC development and exploring strategies to therapeutically block EAC development. 5 The glucose-regulated protein-78 (GRP78) is a key member of the heat shock protein-70 family and an important endoplasmic reticulum (ER) chaperone protein. 13, 14 The ER is an essential organelle required for the synthesis and maturation of membraneassociated and secretory proteins. Pathophysiologic conditions that disrupt the ER result in ER stress, activation of the unfolded protein response and marked upregulation of GRP78. 15 ER stress has been reported to be transmissible to the tumor microenvironment 16 and is activated in EAC. 17 The role of GRP78 in human cancers appears to be multifaceted, and its overexpression has been cited in a wide variety of human cancers, including breast and gynecologic cancers. [18] [19] [20] EAC development has been linked to obesity, 20 and increased secretory activities associated with obesity lead to ER stress, unfolded protein response activation and GRP78 upregulation. 21 Within the uterus, GRP78 overexpression is more frequently apparent in EAC than in normal endometrium. 17, 19, 22 Although benign endometrial epithelial cells will have some basal expression of GRP78, women with EAC whose carcinoma cells exhibit even higher levels of GRP78 expression tend to fare worse, clinically. 22 Furthermore, GRP78 expression levels in visceral adipocytes adjacent to the uterine corpus are also higher in women with EAC who have more worrisome clinical features (for example, myometrial invasion and advanced stage). 22 Although GRP78 is known to be an upstream regulator of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, GRP78 has also been shown to be a downstream target of AKT, an important signal transduction pathway in EAC. 19 In addition, GRP78 is important for the optimal activation of AKT in response to cisplatin in EAC cell lines. 19 Despite these observations, the key question of whether GRP78 is required for EAC development or progression is still not known.
Traditionally, GRP78 is regarded as an ER luminal protein critical for protein folding and processing, degrading malfolded ER proteins and maintaining the transmembrane ER stress sensors and pro-apoptotic components in their inactive forms. 15, [23] [24] [25] Recent discovery of GRP78 localized on the plasma membrane of cancer cells has led to the further characterization that ER stress, as seen in cancer cells due to both intrinsic and extrinsic factors, can actively promote the surface expression of GRP78. 26, 27 At the cell surface, GRP78 forms complexes with PI3K and enhances PI (3, 4, 5) P3 production, consistent with its novel role as a regulator of the PI3K/AKT signaling pathway, which promotes cell proliferation, survival, metastasis, and chemoresistance. 28 Furthermore, the preferential presence of GRP78 on the surface of cancer but not normal cells in vivo provides a potential opportunity for highly specific therapeutic intervention. 26, [29] [30] [31] [32] Recently, a high-affinity, highly specific monoclonal antibody (MAb159) against GRP78 has been identified and has shown therapeutic efficacy in reducing tumor growth in vivo. 32 In this study, we used a combined approach of genetic knockout and antibody targeting of GRP78 to provide direct evidence that GRP78 is critical and necessary for the development of Pten-driven EAC, and may represent a new therapeutic opportunity for EAC.
RESULTS
Creation of biallelic deletion of Grp78 and Pten in the mouse uterus Across successive breeding generations, PCR analysis of female pups at 10 days confirmed the generation of the distinct genotypes used throughout these studies: cPten f/f Grp78 +/+ , cPten f/f Grp78 f/+ and cPten f/f Grp78 f/f with mice lacking Cre expression serving as wildtype (WT) mice. Mouse tail genomic DNA was used for genotyping and the status of Pten and Grp78 alleles in the uterus was confirmed by PCR of uterine DNA analyzed at 8 weeks ( Figure 1a ).
Immunohistochemical staining of uterine cross-sections first showed PR primarily localized in the endometrium (Figure 1b ). Loss of expression of the targeted genes within the endometrium was then confirmed by immunohistochemical analysis (Figure 1b ). GRP78 and PTEN protein expression was detected in the uteri of WT mice, while expression of both proteins was substantially reduced in the endometria from cPten f/f Grp78 f/f mice (Figure 1b ). To assess the level and durability of PTEN and GRP78 loss, western blot analysis of tissue lysate from the uteri at 4 and 20 weeks was performed. Reduction or loss of PTEN expression was confirmed at each time point. Similarly, GRP78 expression in the uterus declined significantly in mice homozygous for the Grp78 floxed alleles compared with the uteri from WT mice ( Figure 1c ). Interestingly, we noted that for the cPten f/f Grp78 f/+ mice, the expression level of GRP78 was only modestly reduced at 4 weeks, and by 20 weeks its level was similar to that of WT mice, thereby suggesting a compensatory response in the heterozygous mice to restore normal levels of GRP78 (Figure 1c ). Immunohistochemical evaluation of GRP78 expression in formalin-fixed paraffin-embedded (FFPE) uterine sections further confirmed durable and near-absent GRP78 expression within the endometrial epithelial cells of cPten f/f Grp78 f/f uteri at both 4 and 8 weeks ( Figure 1d ).
Conditional Grp78 deletion from the endometrium blocks endometrial cancer development To determine whether anatomic differences existed in the murine uteri from different genotypes, biometric data were taken from euthanized mice ( Table 1 ). The mean uterine weights between cPten f/f Grp78 f/f and WT mice were not statistically different at 10 days and 4 weeks (Table 1) . However, by 4 weeks the mean uterine weights of cPten f/f Grp78 +/+ mice were significantly greater than that of both WT and cPten f/f Grp78 f/f mice. cPten f/f Grp78 +/+ mice at 8 weeks showed the greatest mean uterine weight compared with cPten f/f Grp78 f/+ and cPten f/f Grp78 f/f mice ( Figure 2 ). There was no statistically significant difference in mean uterine weights between cPten f/f Grp78 +/+ and cPten f/f Grp78 f/+ mice at both 4 and 8 weeks (Table 1) .
To account for any variability in constitutive differences in mouse size, uterine weights were individually normalized against the total body weights. There was no statistically significant difference in mean total body weights or normalized uterine weights across the cPten f/f Grp78 +/+ , cPten f/f Grp78 f/+ and cPten f/f Grp78 f/f mice at 10 days, regardless of their Grp78 status (P-values 40.7, Figure 2 ). However, at 4 and 8 weeks, both cPten f/f Grp78 +/+ and cPten f/f Grp78 f/+ mice had significantly greater normalized uterine weights compared with WT and cPten f/f Grp78 f/f mice (both Po 0.01, Figure 2 ). Although the normalized uterine weights for 4-week-old WT and cPten f/f Grp78 f/f mice were similar, interestingly, normalized uterine weights from cPten f/f Grp78 f/f mice at 8 weeks were also significantly smaller than that from WT mice (P = 0.01, Figure 2 ). EAC is histologically undetectable after conditional Grp78 deletion from the endometrium To determine whether GRP78 blocked or delayed EAC development, the uteri from all mice were anatomically and histologically evaluated from 10 days onwards by a gynecologic pathologist (PMF). Anatomic inspection of uteri at 4 and 8 weeks showed no morphologic differences between cPten f/f Grp78 f/f and WT mice ( Figure 3a ). Histologically, uteri from cPten f/f Grp78 +/+ mice as early as 10 days showed complex atypical hyperplasia (CAH) and welldifferentiated (that is, Grade 1) EAC was observed as early as 11 days (Figure 3b ). EAC was seen in 82% of cPten f/f Grp78 +/+ mice and 92% of cPten f/f Grp78 f/+ mice by 4 weeks (Figure 3c ). At 8 weeks, 80% of cPten f/f Grp78 +/+ mice and 94% of cPten f/f Grp78 f/+ mice demonstrated EAC. Remarkably, however, at 4 and 8 weeks, no EAC was observed in the cPten f/f Grp78 f/f mice (all P-values o0.001; Figure 3c ).
To characterize whether EAC development was halted or delayed, we performed necropsies of the cPten f/f Grp78 f/f mice at 4 and 5 months. At both time points, no cases of EAC were identified ( Figure 4 ). In contrast, 80% and 100% of cPten f/f Grp78 +/+ and cPten f/ f Grp78 f/+ mice, respectively, developed EAC at 4 months. Mice with both Pten and Grp78 inactivated (cPten f/f Grp78 f/f ) failed to develop any EAC even after 8 months, findings similar to that seen in WT mice (log-rank P = 1.0; Figure 4 ). Collectively, our data demonstrated that homozygous Grp78 deletion completely blocked development of both Pten-mediated EAC and its precursor, CAH, while heterozygous Grp78 deletion could significantly delay EAC development (log-rank P = 0.03; Figure 4 ) but was insufficient to prevent tumor development altogether (log-rank Po0.0001; Figure 4 ).
GRP78 deficiency inhibits AKT activation in Pten-null endometrium AKT activation is an important mechanism in the development and progression of many solid tumors, including this Pten-null EAC model. Recent in vitro evidence shows that GRP78 is needed for optimal AKT activation in EAC; 19 therefore, we sought to determine whether genetic deletion of Grp78 from the endometrial epithelia could block AKT activation in cPten f/f Grp78 f/f uteri. As demonstrated by immunofluorescent staining followed by confocal microscopy, endometrial tumors collected from necropsy showed robust expression of AKT and GRP78 in cPten f/f Grp78 +/+ endometrial epithelial cells ( Figure 5a ). Although AKT was activated in the cPten f/f Grp78 +/+ uteri as evidenced by serine 473 phosphorylation, this activation was markedly suppressed in the cPten f/f Grp78 f/f uteri, correlating with the lack of GRP78 expression ( Figure 5a ). This result was confirmed in western blottings using lysates from WT, cPten f/f Grp78 +/+ and cPten f/f Grp78 f/f uteri (Figure 5b ). We further determined that S6 phosphorylation (serine 235/236), which is downstream of AKT activation, was also suppressed in cPten f/f Grp78 f/f uteri (Figure 5c ). Dual immunofluorescent staining of pAKT and GRP78 in 4-week cPten f/f Grp78 +/+ uteri further demonstrated that GRP78 co-localized with pAKT at the cell surface (Figure 5d ). Unfolded protein response activation is often associated with tumorigenesis. 15 In the Pten-null EAC model, eukaryotic initiation factor-2α phosphorylation downstream of protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling was observed in the cancerous cPten f/f Grp78 +/+ uteri but not in the WT (Figure 6 ). Phosphorylation of eukaryotic initiation factor-2α was also detected in the cPten f/f Grp78 f/f uteri, consistent with previous reports of eukaryotic initiation factor-2α activation in GRP78 knockdown in other cell types ( Figure 6 ). 33 In contrast, the expression of CHOP, a pro-apoptotic unfolded protein response marker downstream of the PERK signaling, was detected in only a few cells in the cPten f/f Grp78 +/+ uteri and not detected in the WT or the cPten f/f Grp78 f/f uteri ( Figure 6 ).
Therapeutic targeting of cell surface GRP78 induces endometrial cancer regression
The detection of GRP78 at the surface of EAC cells presents a key opportunity for therapeutic targeting. 34 To test this, 3-week-old cPten f/f Grp78 +/+ mice were randomized to receive either IgG vehicle or the highly specific anti-GRP78 antibody, MAb159, via biweekly intraperitoneal injections for 4 weeks. Uteri were collected at necropsy and examined with a gynecologic pathologist (PMF) blinded to the treatment group. Uteri in both treatment groups were morphologically abnormal with indurated uterine horns; however, MAb159-treated uteri were generally smaller (about 40%) than IgG-treated uteri (Figure 7a ). After 4 weeks of treatment, uterine cross-sections from the IgG group showed well-differentiated EAC defined as and as evidenced by back-to-back endometrial glands exhibiting hyperchromatic nuclei and prominent nucleoli (Figure 7b ). There are also focal areas with superficial myometrial invasion. Uteri from the MAb159-treated group also showed similar morphology as those in the IgG-treated group, but MAb159-treated uteri also showed larger areas of necrosis than their IgG counterparts (Figure 7b ). To determine whether or not GRP78-targeting therapy is capable of suppressing AKT and S6 activation, we analyzed the uteri from cPten f/f Grp78 +/+ mice for pAKT and pS6. Both AKT and S6 activation were observed in established cPten f/f Grp78 +/+ EAC tumors at 7 weeks (Figure 7c ). Therapeutic delivery of MAb159 against cell surface GRP78 mitigates AKT and S6 activation, and results in decreased expression of pro-tumorigenic pAKT and pS6. Furthermore, TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) staining revealed an increase in apoptotic cells after MAb159-treatment compared with IgG-vehicle-treated cells (Figure 7c ), which, taken together, provides additional support for GRP78 as a therapeutic target for EAC treatment by suppressing AKT activation and increasing apoptosis.
DISCUSSION
We use a conditional knockout mouse model of EAC to demonstrate that the specific ablation of GRP78 from the endometrium inhibits AKT activation, while durably preventing PTEN-mediated EAC development even beyond 300 days of life.
Another key finding of particular importance in our work was the prevention of the EAC precursor, CAH, after tissue-specific GRP78 knockout. Furthermore, we also show that homozygous Grp78 deletion in the endometrial epithelial cells not only prevents EAC development, it also interrupts and attenuates AKT activation mediated by PTEN loss. Interestingly, re-expression of GRP78 to the WT level was observed in mice still harboring a single functional Grp78 allele, suggesting some compensatory response to restore normal GRP78 levels. Although the EAC tumor formation was delayed in these mice, they eventually developed EAC, similar to the cPten f/f Grp78 +/+ mice. Importantly, with GRP78 detectable on the surface of the EAC cells, we show that GRP78 is therapeutically targetable with a monoclonal antibody, and that GRP78-targeted therapy results in reduction of AKT activation and increased areas of tumoral apoptosis. The critical role of GRP78 in the development of several human cancers and the manifestation of chemo-or hormone-resistant phenotypes is well documented. 18, 35, 36 Higher GRP78 expression levels in tumors have been correlated with more aggressive tumor characteristics (for example, invasion and lymph node involvement) and worse clinical outcome (for example, survival). 14 The level of GRP78 expression in clinical samples of invasive breast carcinoma has been shown to predict responsiveness to certain cytotoxic chemotherapies, such as anthracyclines and alkylating agents. 18, 37 Meanwhile, in cell lines, high GRP78 levels appear to be associated with aggressive phenotypes, including increased growth, invasiveness, decreased apoptosis and increased survival. 34, 38 GRP78 also has an integral role in several critical cell signaling pathways, many of which (for example, PI3K/AKT), figure prominently in human cancers. 39 In vitro and in vivo cancer models support the relationship between GRP78 and AKT activation. 14, 27, 32, 40, 41 For example, in PTEN-loss-driven prostate cancer and leukemia, a partial reduction of GRP78 suppresses AKT activation. 6, 7 However, how GRP78 affects AKT activation could be multifactorial. Although GRP78 is generally regarded as an ER-resident protein, a subfraction of GRP78 localizes at the cell surface in selected cell types, notably cancer cells. 27, 41 Cell surface GRP78, through its interaction with different ligands and cell surface proteins, can mediate important signal transduction pathways including PI3K/AKT and this could have a major role, as MAb159 targeting cell surface GRP78 is highly effective in suppressing AKT activation in a variety of tumors, including EAC. However, it is also possible that, as a major molecular chaperone in the ER, GRP78 may be required for processing important growth factors and the cell surface expression of their corresponding receptors, which might regulate AKT activation.
One proposed mechanism in which cell surface GRP78 activates AKT is by complexing with PI3K to promote phosphatidylinositol (3,4,5)-trisphosphate formation. 28 Consistent with this notion, colocalization of GRP78 with pAKT on the cell surface in Pten-null EAC was detected, similar to the phenomena seen in pancreatic adenocarcinoma. 42 Collectively, we report here for the first time that, in this murine Pten-null EAC, endometrium-specific GRP78 deletion is able to suppress AKT and S6 activation. Our targeted genetic deletion of GRP78 using floxed murine models provides compelling evidence to explore and identify pharmacologic means to block GRP78 and further represents a therapeutic opportunity to exploit this target. 14, 30 In endometrial cancer, perturbation of cell surface GRP78 with a polyclonal antibody directed against its C-terminus induced apoptosis in AN3CA cells in vitro in association with reduced AKT phosphorylation. 34 We have recently identified a highly specific monoclonal antibody against GRP78 that is capable of inhibiting PI3K/AKT activation and suppressing tumorigenesis, thus representing a new anti-cancer therapeutic strategy. 32 In the current study, monoclonal antibody targeting of GRP78 in vivo not only resulted in decreased tumor with increased tumoral apoptosis but also in the suppression of AKT activation, further supporting the interplay between GRP78 and AKT during EAC development and growth. Given the pleiotropic role of GRP78 in tumorigenesis and progression, additional mechanisms for this anti-tumor phenotype toward interruption of endometrial epithelial cell growth and maturation merits further exploration.
In the decades since identifying the link between EAC, obesity and hyperestrogenism, significant progress has been made to better understand the molecular and genetic underpinnings of endometrial carcinoma. 43 The whole-genome characterization of endometrial carcinomas by The Cancer Genome Atlas further implicates PTEN mutations and co-existing AKT pathway alterations as common genomic events early in the development of EAC. 2 EACs are clearly the more prevalent form of EAC, accounting for 465% of all EACs. This type of EAC also has a recognizable precancerous state, CAH, which is blocked experimentally by tissue-specific GRP78 deletion. Given the pervasiveness of EAC due to the obesity epidemic, preventive and therapeutic strategies to block obesity-related CAH and EAC carry significant potential to deliver a tremendous public health impact.
MATERIALS AND METHODS

Mouse models
The parental male mouse PR Cre/+ Pten f/f on a C57BL6/129SV genetic background 5 was mated with parental female mouse Pten f/f Grp78 f/f on a C57/BL6xDBA2/129 genetic background. 6 These mice were then crossed over successive generations to yield, first, PR Cre/+ Pten f/f Grp78 f/+ mice, then PR Cre/+ Pten f/f Grp78 f/f (cPten f/f Grp78 f/f ) mice ( Supplementary Figure 1) . Mice without the PR Cre/+ allele served as the phenotypic WT controls. All animal experiments were conducted in concordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals after protocol approval from the USC Institutional Animal Care and Use Committee. Genotyping of tail or uteri genomic DNA were performed using PCR primers ( Supplementary Table 1 ) as previously described. 5, 6 At various time points, all uteri were collected, weighed and measured at the time of necropsy, just before snap freezing for tissue lysate or fixation in 10% buffered formalin for microscopic examination. Tissue morphology was examined after hematoxylin-eosin staining of 5-μm-thick FFPE sections. All histologic diagnoses were rendered by a gynecologic pathologist with expertise in gynecologic cancers (PMF). slides as previously described. 6 Briefly, after deparaffinization and rehydration, standard antigen retrieval (Retrievagen A, BD Biosciences, San Jose, CA, USA) and blocking of endogenous peroxidases (3% H 2 O 2 / phosphate-buffered saline) and nonspecific epitopes (5% normal horse serum) were performed. Sections were incubated with the appropriate primary antibody overnight at 4°C with the appropriate negative control. Detection was performed using the antibody-specific Vectastain Elite Avidin-Biotin Complex (ABC) kit (Vector Laboratories, Burlingame, CA, USA) and visualization was achieved with 3,3′-diaminobenzidine (BD Biosciences) and Gill's No. 3 hematoxylin (Sigma-Aldrich, St Louis, MO, USA) counterstaining.
Immunohistochemical staining
Phospho-AKT (Ser473, Cell Signaling) and phospho-S6 (Ser235/236 Cell Signaling), immunohistochemistry was performed on FFPE sections, as previously described. 32 Briefly, sections were de-waxed and rehydrated before endogenous peroxidases and nonspecific epitopes were blocked. Incubation with the respective primary antibody was performed overnight, followed by counterstaining and visualization, as previously described. 32 Images were acquired with an Olympus BX51 microscope (Olympus America, Inc., Center Valley, PA, USA) and Image-Pro+ (Version 6.0; Media Cybernetics, Inc., Rockville, MD, USA).
Immunofluorescent staining and TUNEL
Freshly cut FFPE sections were evaluated by immunofluorescent staining, as previously described. 6 The following primary antibodies were used: anti-GRP78 (C-20; Santa Cruz Biotechnology; 1:50), anti-phospho-AKT (Ser473) (D9E XP; Cell Signaling Technology, Danvers, MA, USA; 1:50), anti-phospho-S6 (Ser235/236, Cell Signaling; 1:100) and anti-S6 (Cell Signaling; 1:100). DAPI (4',6-diamidino-2-phenylindole) was used for nuclear staining. Immunofluorescence was analyzed by Zeiss LSM 510 confocal microscope with LSM 510 Version 4.2 SP1 acquisition software (Zeiss, Thornwood, NY, USA). Confocal images were acquired with × 40 and × 100 oil lens, and processed with LSM Image Browser R4.2 and Adobe Photoshop CS5 (Adobe Systems Incorporated, San Jose, CA, USA).
Apoptosis was measured using the TUNEL fluorescent kit (Promega, Madison, WI, USA) on FFPE sections, according to the manufacturer's instructions, as previously described. 44 The percentage of TUNEL-positive cells was determined using ImageJ (National Institutes of Health, Bethesda, MD, USA).
Western blot analysis
Snap-frozen murine uteri collected at necropsy were homogenized (OMNI tissue master) in cold M-PER (mammalian protein extraction reagent) supplemented with cComplete, Mini and phosStop phosphatase inhibitor (Roche, Mannheim, Germany) on ice. The protein was extracted after the lysate was centrifuged (4°C, 14 000 r.p.m., 10 min) and quantified using the Bradford assay kit (Bio-Rad Laboratories, Hercules, CA, USA). As previously described, 19 20 μg of lysate was run on a 10% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. Nonspecific epitopes were blocked with Odyssey blocking buffer (Li-COR, Lincoln, NE, USA) and membranes were incubated with the appropriate primary antibodies-anti-GRP78 (1:2000, Abcam), anti-pAKT (Ser473) (1:1000, Cell Signaling), anti-AKT (1:1000) and anti-PTEN (1:1000, Cell Signaling) overnight at 4°C. Vinculin (1:5000, Sigma-Aldrich Corp., St Louis, MO, USA) served as a loading control. Odyssey secondary antibodies (goat anti-rabbit IRDye680 and goat anti-mouse IRDye800) were used as appropriate, and proteins were visualized and quantified using the Li-COR Odyssey CLx Infrared Imaging System (LI-COR).
In vivo monoclonal antibody treatment
Three-week-old cPten f/f Grp78 +/+ mice were randomized into two treatment groups: IgG-vehicle and MAb159, a highly specific anti-GRP78 antibody. The mice were treated with either IgG-vehicle or MAb159 (10 mg/kg) by intraperitoneal injection twice weekly for 4 weeks after which time mice were euthanized. Uteri were collected at necropsy for analysis.
Statistical analysis
Data regarding mouse and uterine weights are expressed as mean ± s.d. The Mann-Whitney rank-sum test was used to analyze non-parametric and non-normally distributed data. Log-rank analyses were used to compare survival curves. A two-tailed P-value o 0.05 was considered statistically significant. Analyses were performed using GraphPad (Prism Version 5, La Jolla, CA, USA). 
